Prima BioMed Receives $777K R&D Tax Incentive Refund
(firmenpresse) - SYDNEY, AUSTRALIA -- (Marketwired) -- 01/20/15 -- Prima BioMed Ltd (NASDAQ: PBMD) (ASX: PRR) ("Prima") is pleased to advise that it has received approximately $777k in a cash rebate from the Australian Federal Government's R&D tax incentive program. The cash rebate was provided essentially in respect of expenditures incurred on eligible Australian R&D activities conducted on the CVac clinical trials during the 2014 financial year.
Prima BioMed is a globally active biotech company developing immunotherapeutic products for the treatment of cancer. Prima is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value for its shareholders. Following the acquisition of Immutep SA, Prima owns a number of different immunotherapy products in preclinical and clinical development.
Stuart Roberts
+61 (0) 447 247 909
Adam Holdsworth
ProActive Capital
+1 (646) 862 4607
Mr. Matthew Gregorowski
Citadel Communications
+61 (0) 422 534 755
Mr. Axel Muhlhaus
edicto GmbH
+49 (0) 69 905505-52
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 20.01.2015 - 13:53 Uhr
Sprache: Deutsch
News-ID 365544
Anzahl Zeichen: 0
contact information:
Town:
SYDNEY, AUSTRALIA
Kategorie:
Trials
Diese Pressemitteilung wurde bisher 183 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Prima BioMed Receives $777K R&D Tax Incentive Refund"
steht unter der journalistisch-redaktionellen Verantwortung von
Prima BioMed Ltd (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
